DrugPatentWatch Database Preview
Drugs in Development Information for Bombesin
» See Plans and Pricing
What is the drug development status for Bombesin?
Bombesin is an investigational drug.
There have been 15 clinical trials for Bombesin.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2017.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Breast Neoplasms, and Glioma. The leading clinical trial sponsors are Peking Union Medical College Hospital, National Institute for Biomedical Imaging and Bioengineering (NIBIB), and Stanford University.
There are three hundred and sixteen US patents protecting this investigational drug and four international patents.
Summary for Bombesin
US Patents | 316 |
International Patents | 4,773 |
US Patent Applications | 0 |
WIPO Patent Applications | 0 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 1 (2017-05-01) |
Vendors | 0 |
Recent Clinical Trials for Bombesin
Title | Sponsor | Phase |
---|---|---|
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer | Stanford University | Phase 2 |
68Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer | General Electric | Phase 1/Phase 2 |
68Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer | Stanford University | Phase 1/Phase 2 |
Clinical Trial Summary for Bombesin
Top disease conditions for Bombesin
Top clinical trial sponsors for Bombesin
US Patents for Bombesin
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Bombesin | Start Trial | Water soluble membrane proteins and methods for the preparation and use thereof | Massachusetts Institute of Technology (Cambridge, MA) | Start Trial |
Bombesin | Start Trial | Therapeutic fusion proteins | Ipsen Bioinnovation Limited (Abingdon, Oxfordshire, GB) | Start Trial |
Bombesin | Start Trial | Radiolabeled active targeting pharmaceutical composition and the use thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (Longtan Township, TW) | Start Trial |
Bombesin | Start Trial | Methods for screening for binding partners of G-protein coupled receptors | Heptares Therapeutics Limited (Hertfordshire, GB) | Start Trial |
Bombesin | Start Trial | Recombinant polypeptides for membrane fusion and uses thereof | Entos Pharmaceuticals Inc. (Edmonton, CA) | Start Trial |
Bombesin | Start Trial | Methods for quantifying polypeptides using mass spectrometry | WATERS TECHNOLOGIES CORPORATION (Milford, MA) | Start Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bombesin
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Bombesin | Australia | AU2012220558 | 2031-02-23 | Start Trial |
Bombesin | Australia | AU2016201914 | 2031-02-23 | Start Trial |
Bombesin | Australia | AU2017261525 | 2031-02-23 | Start Trial |
Bombesin | Brazil | BR112013020969 | 2031-02-23 | Start Trial |
Bombesin | Canada | CA2827187 | 2031-02-23 | Start Trial |
Bombesin | Chile | CL2013002419 | 2031-02-23 | Start Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |